DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/j64ntb/us_and_europe) has announced the addition of the "US & Europe Markets for Bone Morphogenetic Protein Growth Factor Therapy - 16 Countries (2011-2021)" report to their offering.
Bone morphogenetic proteins (BMPs) are growth factors that induce the formation of bone after a fracture. In nature, these proteins have a critical role during embryonic development in the formation of the skeleton. There are twenty different BMPs that have been discovered thus far, of which only two, BMP-2 and BMP-7, have been commercialized as bone graft substitutes for use in specific orthopedic procedures. The commercial versions of these products are produced by recombinant genetic engineering, which results in a recombinant human protein.
The recombinant human BMP-2 (rhBMP-2) is marketed as a commercial product by Medtronic, Inc. and is called Infuse® (InductOS® in Europe), while BMP-7 has been commercialized by Stryker Inc. and is sold to Olympus under the name of OP-1®. Both molecules mediate the process of osteoblast differentiation. BMP-2 is capable of stimulating immature mesenchymal cells to form into bone, while BMP-7 has been shown to be capable of stimulating cartilage growth.
Key Topics Covered:
- Research Methodology
- European Country Profiles
- European Bone Morphogenetic Protein Growth Factor Therapy Market
- U.S. Bone Morphogenetic Protein Growth Factor Therapy Market
For more information visit http://www.researchandmarkets.com/research/j64ntb/us_and_europe